康乃德生物 CNTB 深 滬
等待開盤 08-08 09:30:00 美东时间
2.07
-0.060
-2.82%
華盛通- 最 高2.26
- 今 開2.19
- 成交量 8.12万股
- 最 低 1.9166
- 昨 收 2.13
- 總市值 1.15亿
- 52周最高 2.86
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.51
- 委 比 -39.55%
- 總股本 5556.11万
- 歷史最高 29.274
- 量 比 0.55
- 振 幅 16.12%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Connect Biopharma Expands Board, Appoints New Director
Connect Biopharma Holdings ( ($CNTB) ) just unveiled an update. On July 22, 202...
07-22 21:28
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Medpace Hldgs (NASDAQ:MEDP) shares moved upwards by 44.6% to $446.6 du...
07-22 20:07
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
Connect Biopharma Holdings Limited has expanded its Board of Directors to seven members, appointing Jim Schoeneck as a new director. Schoeneck, a seasoned biotech leader with over 40 years of experience, brings expertise in drug development and commercialization, expected to accelerate progress for the company's lead drug candidate, rademikibart. Rademikibart is a next-generation antibody targeting IL-4Rα, currently in Phase 2 trials for treating...
07-22 13:00
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
Connect Biopharma宣布终止存托协议，计划将存托凭证转换为普通股并于2025年9月2日在纳斯达克直接上市。此举旨在提高机构可见度，减少费用，并拓展投资者基础。公司专注于哮喘和慢性阻塞性肺病的治疗，其药物rademikibart正在推进II期临床试验。
07-21 13:00
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
Connect Biopharma Holdings Limited (NASDAQ: CNTB), a clinical-stage biopharmaceutical company focused on inflammatory diseases, announced that its management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29, 2025. The company is advancing rademikibart, a next-generation antibody targeting IL-4Rα, for the treatment of asthma and COPD. Connect has an exclusive license for rademikibart in China through a co...
07-18 13:00
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Connect Biopharma Holdings Limited (CNTB) has regained compliance with Nasdaq's minimum bid price requirement after its ADSs maintained a closing bid price of at least $1.00 for 10 consecutive business days. This ensures its ADSs remain listed and traded on Nasdaq. The Company, focused on treating inflammatory diseases like asthma and COPD, is advancing rademikibart, an antibody targeting IL-4Rα, with global clinical studies underway. Connect Bio...
07-17 13:00
周专题&周观点：A/H器械公司25H1涨幅榜前20缘何强势？【总第405期】【国盛医药】
（转自：国医盛视） 一、医药核心观点 当周（7.7-7.11）回顾与周专题： 当周（7.7-7.11）申万医药指数环比+1.82%，跑输创业板...
07-12 19:37
先声药业乐德奇拜单抗申报上市，IL-4Rα 靶点竞争再升温
2025年7月8日，先声药业IL-4Rα单克隆抗体乐德奇拜单抗在国内申报上市。该药由康乃德生物研发，先声药业以10.25亿元获得其在大中华区的独家权益。作为一种...
07-10 18:04
Connect Biopharma Holdings Announces Company's Collaborator And Exclusive Licensee in China, Simcere Pharmaceutical Has Submitted Its New Drug Application For Rademikibart To The National Medical Products Administration Of China For The Treatment Of Atopic Dermatitis
Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases,
07-09 21:02
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
Connect Biopharma announced that its Chinese collaborator, Simcere Pharmaceutical, has submitted a New Drug Application (NDA) to the National Medical Products Administration (NMPA) for rademikibart, targeting atopic dermatitis (AD) in adults and adolescents. As a next-generation IL-4Rα antibody, rademikibart has potential to address unmet needs in AD, asthma, and COPD. In 2023, Connect and Simcere entered an exclusive license agreement for rademi...
07-09 13:00
